ProCE Banner Activity

ACE-CL-003: Phase Ib/II Study of Acalabrutinib + Obinutuzumab in Patients With Untreated or R/R CLL

Slideset Download
Conference Coverage
The combination of acalabrutinib and obinutuzumab yielded ORR rates exceeding 90% that deepened over time, along with a favorable safety profile.

Released: December 15, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology